Bradley A Maron

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5642744/publications.pdf

Version: 2024-02-01

125 papers	5,221 citations	87843 38 h-index	91828 69 g-index
125 all docs	125 docs citations	125 times ranked	6168 citing authors

#	Article	IF	Citations
1	Genetic Misdiagnoses and the Potential for Health Disparities. New England Journal of Medicine, 2016, 375, 655-665.	13.9	602
2	Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nature Medicine, 2007, 13, 189-197.	15.2	306
3	Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Circulation, 2016, 133, 1240-1248.	1.6	289
4	MicroRNA-21 Integrates Pathogenic Signaling to Control Pulmonary Hypertension. Circulation, 2012, 125, 1520-1532.	1.6	246
5	The Treatment of Hyperhomocysteinemia. Annual Review of Medicine, 2009, 60, 39-54.	5.0	241
6	Aldosterone Inactivates the Endothelin-B Receptor via a Cysteinyl Thiol Redox Switch to Decrease Pulmonary Endothelial Nitric Oxide Levels and Modulate Pulmonary Arterial Hypertension. Circulation, 2012, 126, 963-974.	1.6	171
7	Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respiratory Medicine,the, 2020, 8, 873-884.	5.2	139
8	Moving Beyond the Sarcomere to ExplainÂHeterogeneity in HypertrophicÂCardiomyopathy. Journal of the American College of Cardiology, 2019, 73, 1978-1986.	1.2	124
9	Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension. JAMA Cardiology, 2017, 2, 1361.	3.0	122
10	The Invasive Cardiopulmonary Exercise Test. Circulation, 2013, 127, 1157-1164.	1.6	116
11	PVDOMICS. Circulation Research, 2017, 121, 1136-1139.	2.0	113
12	Diagnosis, Treatment, and Clinical Management of Pulmonary Arterial Hypertension in the Contemporary Era. JAMA Cardiology, 2016, 1, 1056.	3.0	99
13	The Role of the Reninâ€Angiotensinâ€Aldosterone System in the Pathobiology of Pulmonary Arterial Hypertension (2013 Grover Conference Series). Pulmonary Circulation, 2014, 4, 200-210.	0.8	96
14	Effectiveness of Spironolactone Plus Ambrisentan for Treatment ofÂPulmonary Arterial Hypertension (from the [ARIES] Study 1 and 2 Trials). American Journal of Cardiology, 2013, 112, 720-725.	0.7	92
15	Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study. European Journal of Heart Failure, 2013, 15, 277-283.	2.9	91
16	Thermodilution vs Estimated Fick Cardiac Output Measurement in Clinical Practice. JAMA Cardiology, 2017, 2, 1090.	3.0	91
17	Aldosterone Increases Oxidant Stress to Impair Guanylyl Cyclase Activity by Cysteinyl Thiol Oxidation in Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 2009, 284, 7665-7672.	1.6	89
18	NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension. Science Translational Medicine, 2018, 10, .	5.8	89

#	Article	IF	Citations
19	Aldosterone Receptor Antagonists. Circulation, 2010, 121, 934-939.	1.6	86
20	Mild Pulmonary Hypertension Is Associated With Increased Mortality: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2018, 7, e009729.	1.6	86
21	Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension. Circulation, 2015, 131, 2079-2091.	1.6	83
22	S-Nitrosothiols and theS-Nitrosoproteome of the Cardiovascular System. Antioxidants and Redox Signaling, 2013, 18, 270-287.	2.5	79
23	The application of big data to cardiovascular disease: paths to precision medicine. Journal of Clinical Investigation, 2020, 130, 29-38.	3.9	74
24	Association of Mild Echocardiographic Pulmonary Hypertension With Mortality and Right Ventricular Function. JAMA Cardiology, 2019, 4, 1112.	3.0	73
25	Protocol for Exercise Hemodynamic Assessment: Performing an Invasive Cardiopulmonary Exercise Test in Clinical Practice. Pulmonary Circulation, 2015, 5, 610-618.	0.8	68
26	Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1472-1487.	2.5	68
27	Cardiopulmonary Hemodynamics in Pulmonary Hypertension and HeartÂFailure. Journal of the American College of Cardiology, 2020, 76, 2671-2681.	1.2	66
28	Intratracheal Gene Delivery of SERCA2a Ameliorates Chronic Post-Capillary Pulmonary Hypertension. Journal of the American College of Cardiology, 2016, 67, 2032-2046.	1.2	62
29	Immunoglobulin-driven Complement Activation Regulates Proinflammatory Remodeling in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 224-239.	2.5	60
30	Subcellular Localization of Oxidants and Redox Modulation of Endothelial Nitric Oxide Synthase. Circulation Journal, 2012, 76, 2497-2512.	0.7	58
31	Clinical Profile and Underdiagnosis of Pulmonary Hypertension in US Veteran Patients. Circulation: Heart Failure, 2013, 6, 906-912.	1.6	54
32	Upregulation of Steroidogenic Acute Regulatory Protein by Hypoxia Stimulates Aldosterone Synthesis in Pulmonary Artery Endothelial Cells to Promote Pulmonary Vascular Fibrosis. Circulation, 2014, 130, 168-179.	1.6	53
33	Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes. Nature Communications, 2021, 12, 873.	5.8	53
34	Elevated pulmonary vascular resistance predicts mortality in COPD patients. European Respiratory Journal, 2021, 58, 2100944.	3.1	47
35	Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2017, 10, e003689.	1.6	43
36	Network Analysis to Risk Stratify Patients With Exercise Intolerance. Circulation Research, 2018, 122, 864-876.	2.0	42

#	Article	IF	Citations
37	T<scp>ranslational</scp>A<scp>dvances</scp><scp>in</scp><scp>the</scp>F<scp>ield</scp><scp>of</scp>P<scp>ulmonary</scp>H on Developmental Origins and Disease Inception for the Prevention of Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 292-301.	2.5	42
38	Redefining pulmonary hypertension. Lancet Respiratory Medicine,the, 2018, 6, 168-170.	5.2	41
39	Upâ€regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension. FASEB Journal, 2016, 30, 2511-2527.	0.2	39
40	Functional impact of exercise pulmonary hypertension in patients with borderline resting pulmonary arterial pressure. Pulmonary Circulation, 2017, 7, 654-665.	0.8	38
41	Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside. Clinical Epigenetics, 2021, 13, 66.	1.8	36
42	MicroRNA Dysregulation in Pulmonary Arteries from Chronic Obstructive Pulmonary Disease. Relationships with Vascular Remodeling. American Journal of Respiratory Cell and Molecular Biology, 2018, 59, 490-499.	1.4	34
43	Impact of the New Pulmonary Hypertension Definition on Heart Transplant Outcomes. Chest, 2020, 157, 151-161.	0.4	31
44	Paradoxical Embolism. Circulation, 2010, 122, 1968-1972.	1.6	29
45	The Heterogeneity of Clinical Practice Patterns among an International Cohort of Pulmonary Arterial Hypertension Experts. Pulmonary Circulation, 2014, 4, 441-451.	0.8	28
46	A Concerning Trend for Patients With Pulmonary Hypertension in the Era of Evidence-Based Medicine. Circulation, 2019, 139, 1861-1864.	1.6	23
47	Network medicine in Cardiovascular Research. Cardiovascular Research, 2021, 117, 2186-2202.	1.8	23
48	Pulmonary Hypertension: Pathophysiology and Signaling Pathways. Handbook of Experimental Pharmacology, 2013, 218, 31-58.	0.9	23
49	Role of Pulmonary Artery Wedge Pressure Saturation During Right Heart Catheterization. Circulation: Heart Failure, 2020, 13, e007981.	1.6	22
50	Sex-based differences in veterans with pulmonary hypertension: Results from the veterans affairs-clinical assessment reporting and tracking database. PLoS ONE, 2017, 12, e0187734.	1.1	21
51	Homocysteine. Clinics in Laboratory Medicine, 2006, 26, 591-609.	0.7	19
52	Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysis. Journal of Heart and Lung Transplantation, 2020, 39, 289-299.	0.3	19
53	A global network for network medicine. Npj Systems Biology and Applications, 2020, 6, 29.	1.4	19
54	Harnessing Big Data to Advance Treatment and Understanding of Pulmonary Hypertension. Circulation Research, 2022, 130, 1423-1444.	2.0	19

#	Article	IF	Citations
55	Should hyperhomocysteinemia be treated in patients with atherosclerotic disease?. Current Atherosclerosis Reports, 2007, 9, 375-383.	2.0	18
56	Building the Case for Novel Clinical Trials in Pulmonary Arterial Hypertension. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 114-123.	0.9	18
57	Claimsâ€Based Algorithms for Identifying Patients With Pulmonary Hypertension: A Comparison of Decision Rules and Machineâ€Learning Approaches. Journal of the American Heart Association, 2020, 9, e016648.	1.6	17
58	Inflammation, immunity, and vascular remodeling in pulmonary hypertension; Evidence for complement involvement?. Global Cardiology Science & Practice, 2020, 2020, e202001.	0.3	17
59	Echocardiographic Predictors of Mortality in Patients with Pulmonary Hypertension and Cardiopulmonary Comorbidities. PLoS ONE, 2015, 10, e0119277.	1.1	15
60	NEDD9 Is a Novel and Modifiable Mediator of Plateletâ€“Endothelial Adhesion in the Pulmonary Circulation. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1533-1545.	2.5	14
61	Elevated pulmonary arterial and systemic plasma aldosterone levels associate with impaired cardiac reserve capacity during exercise in left ventricular systolic heart failure patients: A pilot study. Journal of Heart and Lung Transplantation, 2016, 35, 342-351.	0.3	13
62	Renin-Angiotensin-Aldosterone System Inhibitor Use and Mortality in Pulmonary Hypertension. Chest, 2021, 159, 1586-1597.	0.4	13
63	Quantification of Arterial and Venous Morphologic Markers in Pulmonary Arterial Hypertension Using CT Imaging. Chest, 2021, 160, 2220-2231.	0.4	13
64	Mildly elevated pulmonary artery systolic pressure on echocardiography: bridging the gap in current guidelines. Lancet Respiratory Medicine,the, 2021, 9, 1185-1191.	5.2	13
65	Relation of Doppler Tissue Imaging Parameters With Heart Failure Progression in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2016, 117, 1808-1814.	0.7	12
66	Endothelin-1, cardiac morphology, and heart failure: the MESA angiogenesis study. Journal of Heart and Lung Transplantation, 2020, 39, 45-52.	0.3	12
67	Integrating haemodynamics identifies an extreme pulmonary hypertension phenotype. European Respiratory Journal, 2021, 58, 2004625.	3.1	12
68	H2 Receptor Antagonist Use and Mortality in Pulmonary Hypertension: Insight from the VA-CART Program. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1638-1641.	2.5	11
69	Mildly increased pulmonary arterial pressure: a new disease entity or just a marker of poor prognosis?. European Journal of Heart Failure, 2019, 21, 1057-1061.	2.9	11
70	Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. Circulation: Heart Failure, 2021, 14, .	1.6	11
71	Mineralocorticoid receptor antagonists and endothelial function. Current Opinion in Investigational Drugs, 2008, 9, 963-9.	2.3	11
72	Revisiting Athleteâ€™s Heart Versus Pathologic Hypertrophy. JACC: Cardiovascular Imaging, 2017, 10, 394-397.	2.3	10

#	Article	IF	Citations
73	Precision Medicine in Pulmonary Arterial Hypertension. Circulation Research, 2019, 124, 832-833.	2.0	10
74	Usefulness of ventilatory inefficiency in predicting prognosis across the heart failure spectrum. ESC Heart Failure, 2022, 9, 293-302.	1.4	10
75	What Causes Hypertrophic Cardiomyopathy?. American Journal of Cardiology, 2022, 179, 74-82.	0.7	10
76	Study Design and Rationale for Investigating Phosphodiesterase type 5 Inhibition for the Treatment of Pulmonary Hypertension Due to Chronic Obstructive Lung Disease: The TADAâ€PHiLD (TADAlafil for) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Circulation, 2013, 3, 889-897.	0.8	9
77	Hemodynamics Should Be the Primary Approach to Diagnosing, Following, and Managing Pulmonary Arterial Hypertension. Canadian Journal of Cardiology, 2015, 31, 515-520.	0.8	9
78	Pulmonary endothelial NEDD9 and the prothrombotic pathophenotype of acute respiratory distress syndrome due to SARSâ€CoVâ€2 infection. Pulmonary Circulation, 2022, 12, .	0.8	8
79	Protocol for Vasoreactivity Testing With Epoprostenol in Pulmonary Hypertension. Critical Pathways in Cardiology, 2012, 11, 40-42.	0.2	7
80	Pulmonary Vascular and Ventricular Dysfunction in the Susceptible Patient (2015 Grover Conference) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.8	7
81	Isolating pulmonary microvascular endothelial cells ex vivo: Implications for pulmonary arterial hypertension, and a caution on the use of commercial biomaterials. PLoS ONE, 2019, 14, e0211909.	1.1	7
82	Factors Associated With Potentially Inappropriate Phosphodiesterase-5 Inhibitor Use for Pulmonary Hypertension in the United States, 2006 to 2015. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e005993.	0.9	7
83	Outcomes of pulmonary vasodilator use in Veterans with pulmonary hypertension associated with left heart disease and lung disease. Pulmonary Circulation, 2021, 11, 1-12.	0.8	7
84	Explaining Unexplained Dyspnea. Circulation, 2014, 130, 2057-2066.	1.6	6
85	Whatâ€™s in a side effect? The association between pulmonary vasodilator adverse drug events and clinical outcomes in patients with pulmonary arterial hypertension. International Journal of Cardiology, 2017, 240, 386-391.	0.8	6
86	Career Development of Young Physicianâ€“Scientists in the Cardiovascular Sciences. Circulation Research, 2018, 122, 1330-1333.	2.0	6
87	Clarifying the Pulmonary Arterial Hypertension Molecular Landscape Using Functional Genetics. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 488-490.	2.5	6
88	The Case for Bringing Birthweight to Adult Cardiovascular Medicine. American Journal of Cardiology, 2020, 127, 191-192.	0.7	6
89	Comprehensive echocardiographic evaluation of the right heart in patients with pulmonary vascular diseases: the PVDOMICS experience. European Heart Journal Cardiovascular Imaging, 2022, 23, 958-969.	0.5	6
90	Chronic Thromboembolic Pulmonary Hypertension: the Bedside. Current Cardiology Reports, 2021, 23, 147.	1.3	6

#	Article	IF	Citations
91	Finding Pulmonary Arterial Hypertensionâ€"Switching to Offense to Mitigate Disease Burden. JAMA Cardiology, 2022, 7, 369.	3.0	6
92	Independence Day. Circulation, 2016, 133, 2345-2347.	1.6	5
93	Perspectives on Cardiopulmonary Critical Care for Patients With COVIDâ€19: From Members of the American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. Journal of the American Heart Association, 2020, 9, e017111.	1.6	5
94	Cardiovascular Diseases That Have Emerged From the Darkness. Journal of the American Heart Association, 2021, 10, e021095.	1.6	5
95	Towards Widespread Noninvasive Assessment of Pulmonary Vascular Resistance in Clinical Practice. Journal of the American Society of Echocardiography, 2014, 27, 108-109.	1.2	4
96	Association between Pulmonary Hypertension and Clinical Outcomes in Hospitalized Patients with Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 534-537.	2.5	4
97	POINT: Should the New Definition of PH Be the Clinical Practice Standard? Yes. Chest, 2020, 157, 764-766.	0.4	4
98	Chronic Thromboembolic Pulmonary Hypertension: the Bench. Current Cardiology Reports, 2021, 23, 141.	1.3	4
99	Pulmonary arterial hypertension: Cellular and molecular changes in the lung. Global Cardiology Science & Practice, 2020, 2020, e202003.	0.3	4
100	Cardiac catheterization in pulmonary hypertension: doing it right, with a catheter on the left. Cardiovascular Diagnosis and Therapy, 2020, 10, 1718-1724.	0.7	4
101	Pulmonary Hypertension: Good Intentions, But a Questionable Approach. Annals of the American Thoracic Society, 2018, 15, 664-666.	1.5	3
102	Tadalafil for Veterans with Chronic Obstructive Pulmonary Diseaseâ€"Pulmonary Hypertension: A Multicenter, Placeboâ€Controlled Randomized Trial. Pulmonary Circulation, 2022, 12, e12043.	0.8	3
103	Segmental Arterial Mediolysis: An Important but Often Overlooked Cause of Multi-Vessel Thrombosis. American Journal of Medicine, 2018, 131, e231-e234.	0.6	2
104	Toward Early Diagnosis of PulmonaryÂHypertension. Journal of the American College of Cardiology, 2019, 73, 2673-2675.	1.2	2
105	Correspondence on the debate regarding the haemodynamic definition of pulmonary hypertension. European Respiratory Journal, 2019, 53, 1900727.	3.1	2
106	Pulmonary arterial hypertension in the modern era: The intersection of genotype and phenotype. Journal of Heart and Lung Transplantation, 2020, 39, 113-114.	0.3	2
107	COUNTERPOINT: Did the World Symposium on Pulmonary Hypertension Get It Right in Redefining Abnormal Pulmonary Arterial Pressure? No. Chest, 2022, 161, 313-315.	0.4	2
108	HFp2EF: heart failure with pulmonary dysfunction and preserved ejection fraction?. European Heart Journal, 2022, 43, 2209-2211.	1.0	2

#	Article	IF	Citations
109	Emerging Hemodynamic Signatures of the Right Heart (Third International Right Heart Failure Summit,) Tj ETQq1 1 0.784314 rgBT /O	0.8	1
110	The quest for biomarker discovery in pulmonary arterial hypertension: the right takes lessons from the left. Heart, 2016, 102, 335-336.	1.2	1
111	Back to the Future: Building Up the Case for Exploring Red Blood Cell Morphology in Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2019, 16, 548-550.	1.5	1
112	Adding an important piece to the pulmonary vascular resistance puzzle in pulmonary arterial hypertension. European Respiratory Journal, 2020, 56, 2000962.	3.1	1
113	Raptor activation by aldosterone promotes apoptosis resistance in pulmonary artery smooth muscle cells to modulate adverse pulmonary vascular remodeling in pulmonary arterial hypertension. FASEB Journal, 2013, 27, 1199.1.	0.2	1
114	Pulmonary arterial hypertension: Rationale for using multiple vs. single drug therapy. Global Cardiology Science & Practice, 2020, 2020, e202008.	0.3	1
115	Variable Monitoring of Veterans with Group 3 Pulmonary Hypertension Treated with Off-Label Pulmonary Vasodilator Therapy. Annals of the American Thoracic Society, 2022, 19, 1236-1239.	1.5	1
116	TORward a Molecular Convergence Point in Pulmonary Arterial Hypertension WithÂmTOR. JACC Basic To Translational Science, 2018, 3, 763-765.	1.9	0
117	Reply: Can treprostinil-induced early gastrointestinal side effects serve as predictors of pulmonary arterial hypertension prognosis?. International Journal of Cardiology, 2018, 264, 188.	0.8	0
118	In reply, endothelin-1 and the Anrep effect. Journal of Heart and Lung Transplantation, 2020, 39, 847.	0.3	0
119	Rebuttal From Dr Maron. Chest, 2020, 157, 769-770.	0.4	0
120	Adjusting to the New Normal: Echocardiography to Find Pulmonary Hypertension. EClinicalMedicine, 2021, 35, 100867.	3.2	0
121	Aldosterone Activates Autophagy To Increase Fibroblast Collagen Synthesis and Vascular Stiffness. FASEB Journal, 2013, 27, 1188.9.	0.2	0
122	Diagnostic Assessment of the Pulmonary Hypertension Patient. Advances in Pulmonary Hypertension, 2018, 16, 112-119.	0.1	0
123	Pulmonary arterial hypertension: Rationale for using multiple vs. single drug therapy. Global Cardiology Science & Practice, 2020, 2020, e202008.	0.3	0
124	The lamp of medicine of Ancient Egypt is still burning. Global Cardiology Science & Practice, 2020, 2020, e202016.	0.3	0
125	Rebuttal From Drs Johnson and Maron. Chest, 2022, 161, 316-317.	0.4	0